RxDoctor Payments Data

Steven Kapetansky, MD

Family Medicine · Lancaster, OHNPI 1780871343

Payments from drug & device makers

$5,280in general payments, 2019–2025

Across 339 payments — averaging $15.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$1K
  • Pfizer$499
  • Astellas Pharma US Inc$377
  • Novo Nordisk$282
  • Exact Sciences$270
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$5,18598%
  • Education$952%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,280 in reported general payments places this provider in the 85th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$37,490
Medicare patients
120
Services billed
380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban35$32,737
OzempicSemaglutide29$30,432
Tresiba Flextouch U-200Insulin Degludec32$24,374
ArexvyRsvpref3 Antigen/As01e/Pf78$23,934
JanuviaSitagliptin Phosphate22$23,260
XareltoRivaroxaban33$22,348
JardianceEmpagliflozin28$21,192
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$17,307
ShingrixVaricella-Zoster Ge/As01b/Pf41$9,002
Atorvastatin Calcium356$6,180
Tresiba Flextouch U-100Insulin Degludec19$5,431
Memantine Hcl53$3,160
Tamsulosin Hcl91$2,975
Boostrix TdapDiphth,pertuss(Acell),tet Vac33$2,246
Albuterol Sulfate HfaAlbuterol Sulfate86$2,234

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKArexvy, Trelegy Ellipta, Shingrix$102$50,242141 claims
PfizerEliquis$499$32,73735 claims
Novo NordiskOzempic$282$30,43229 claims
MerckJanuvia$30$23,26022 claims
Johnson & JohnsonXarelto$141$22,34833 claims
AbbVieSynthroid$1,033$67420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Lancaster

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →